1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Contraceptives: Executive Summary 2.1 Moderate Growth in the Contraceptives Market Is Expected Between 2017 and 2027, Driven by US and China Sales 2.2 Developers Targeting Other Female Health Conditions in Addition to Contraception 2.3 The Contraceptives Market Is Still in Need of Therapeutics with Better Safety Profiles 2.4 Significant Opportunity Remains in Chinese and Japanese Contraceptives Markets 2.5 The Diverse Late-Stage Pipeline Offers Women More Options for Contraception 2.6 What Do Physicians Think? 3 Introduction 3.1 Catalyst 3.2 Related Reports 3.3 Upcoming Related Reports 4 Disease Overview 4.1 Contraception 4.2 Other Indications 5 Current Treatment Options 5.1 Overview 6 Unmet Needs and Opportunity Assessment 6.1 Overview 6.2 Hormonal Contraceptives with Reduced Adverse Reactions 6.3 Non-hormonal Contraceptives 6.4 Better Compliance and Adherence to Contraceptives 6.5 Access to a Wide Range of Contraceptive Methods 6.6 Awareness of Different Contraceptive Methods 7 R&D Strategies 7.1 Overview 7.1.1 Development of Novel Non-hormonal Contraceptives 7.1.2 Utilization of Contraceptives for Other Disease Indications 7.1.3 New Drug Delivery Technologies 7.2 Clinical Trials Design 7.2.1 Pearl Index as an Efficacy Tool 7.2.2 Selection of an Active Comparator 8 Pipeline Assessment 8.1 Overview 8.2 Innovative Early-Stage Approaches 9 Pipeline Valuation Analysis 9.1 Clinical Benchmark of Key Pipeline Drugs 9.2 Commercial Benchmark of Key Pipeline Drugs 9.3 Competitive Assessment 9.4 Top-Line 10-Year Forecast 9.4.1 US 9.4.2 5EU 9.4.3 Japan 9.4.4 China 10 Appendix 10.1 Bibliography 10.2 Abbreviations 10.3 Methodology 10.3.1 Forecasting Methodology 10.3.2 Percent Drug-Treated Patients 10.3.3 Drugs Included in Each Therapeutic Class 10.3.4 Launch and Patent Expiry Dates 10.3.5 General Pricing Assumptions 10.3.6 Individual Drug Assumptions 10.3.7 Generic Erosion 10.3.8 Pricing of Pipeline Agents 10.4 Primary Research - KOLs Interviewed for This Report 10.5 Primary Research - Prescriber Survey 10.6 About the Authors 10.6.1 Senior Analyst 10.6.2 Managing Analyst 10.6.3 Therapy Area Director 10.6.4 Global Director of Therapy Analysis and Epidemiology 10.6.5 Global Head and EVP of Healthcare Operations and Strategy 10.7 About GlobalData 10.8 Contact Us 10.9 Disclaimer

1.1 List of Tables Table 1: Contraceptives: Key Metrics in the 8MM Table 2: Most Common Types of Contraceptives Table 3: Leading Currently Marketed Branded Contraceptives, 2017 Table 4: Comparison of Therapeutic Classes in Development for Contraception, 2017-2027 Table 5: Innovative Early-Stage Approaches for Contraception, 2018 Table 6: Clinical Benchmark of Key Pipeline Drugs - Contraceptives Table 7: Commercial Benchmark of Key Pipeline Drugs - Contraceptives Table 8: Key Events Impacting Sales for Contraceptives, 2017-2027 Table 9: Contraceptives Market - Global Drivers and Barriers, 2017-2027 Table 10: Key Historical and Projected Launch Dates for Contraceptives Table 11: Key Historical and Projected Patent Expiry Dates for Contraceptives Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, by Country1.2 List of Figures Figure 1: Global Sales Forecast by Country for Contraceptives in 2017 and 2027 Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against Oral Contraceptives Figure 3: Unmet Needs and Opportunities in Contraceptives Figure 4: Overview of the Development Pipeline in Contraception Figure 5: Key Phase II/III Trials for the Promising Pipeline Agents That GlobalData Expects to Be Licensed for Contraception in the 8MM During the Forecast Period Figure 6: Competitive Assessment of the Pipeline Drugs Benchmarked Against Oral Contraceptives Figure 7: Global (8MM) Sales Forecast by Country for Contraceptives in 2017 and 2027 Figure 8: Global Sales Forecast by Class for Contraceptives in 2017 and 2027

Agile Therapeutics Allergan Antares Pharma Bayer ContraMed Exeltis Germany Evofem Biosciences Fuji Pharma Co. Merck Mithra Pharmaceuticals Pfizer The Population Council Sebela Pharma Therapeutics MD Viramal Ltd